A complete analysis of the main efficacy, mechanism of action and scope of indications of tofacitinib (Shangjie)

Tofacitinib is an oral small molecule enzyme inhibitor that belongs to the Janus kinase (JAK) inhibitor family. Its main mechanism of action is to selectively inhibit the activities of JAK1 and JAK3, thereby blocking the signal transduction pathways of multiple pro-inflammatory cytokines and reducing immune cell activation and the release of inflammatory mediators. Through this mechanism, tofacitinib can regulate abnormal immune responses and has a significant therapeutic effect on a variety of autoimmune diseases.

Clinically, the main effects of tofacitinib are to relieve inflammatory symptoms, improve joint function and improve patients' quality of life. Studies show it is effective in controlling disease activity, reducing pain, swelling and stiffness, while reducing levels of inflammatory markers. Tofacitinib has obvious advantages in relieving symptoms in the acute phase of the disease and maintaining long-term remission, and is especially suitable for patients who have poor response to traditional immunosuppressants or biological agents.

Tofacitinib has a wide range of indications and has been approved for the treatment of moderate to severe rheumatoid arthritis (RA), ulcerative colitis (UC) and active psoriatic arthritis (PsA). For patients with rheumatoid arthritis, tofacitinib can be used as a monotherapy or in combination with traditional drugs such as methotrexate; for patients with ulcerative colitis, it can be used in individuals who are hormone-dependent or have responded poorly to other immunosuppressants.

During the medication period, the dose of tofacitinib needs to be adjusted reasonably under the guidance of a doctor, and blood routine, liver and kidney function, and infection risk must be closely monitored. Common side effects include upper respiratory tract infection, elevated blood lipids, mild elevation of liver enzymes, etc. Serious infections or hematological abnormalities are rare but require vigilance. Patients should be careful not to combine it with other immunosuppressive drugs when using it to reduce the risk of infection and ensure both efficacy and safety.

Keyword tag:

Tofacitinib, Shangjie,JAKinhibitors, rheumatoid arthritis, methotrexate, combination therapy, efficacy comparison, treatment advantages, safety and use experience

Reference materials:https://www.ncbi.nlm.nih.gov/books/NBK572148/